[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,536,498
  • Shares Outstanding, K 88,610
  • Annual Sales, $ 172,350 K
  • Annual Income, $ -285,420 K
  • EBIT $ -224 M
  • EBITDA $ -234 M
  • 60-Month Beta 0.38
  • Price/Sales 9.26
  • Price/Cash Flow N/A
  • Price/Book 38.36

Options Overview Details

View History
  • Implied Volatility 85.37% (+9.82%)
  • Historical Volatility 50.49%
  • IV Percentile 58%
  • IV Rank 37.94%
  • IV High 150.01% on 10/16/25
  • IV Low 45.85% on 03/12/26
  • Expected Move (DTE 11) 0.60 (3.43%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 992
  • Volume Avg (30-Day) 1,134
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 19,085
  • Open Int (30-Day) 21,866
  • Expected Range 16.75 to 17.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.45
  • Number of Estimates 5
  • High Estimate $-0.33
  • Low Estimate $-0.67
  • Prior Year $-0.83
  • Growth Rate Est. (year over year) +45.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.90 +2.58%
on 06/04/26
22.69 -23.58%
on 05/11/26
-2.76 (-13.73%)
since 05/05/26
3-Month
16.90 +2.58%
on 06/04/26
25.59 -32.24%
on 03/25/26
-4.24 (-19.65%)
since 03/05/26
52-Week
8.59 +101.98%
on 07/07/25
25.59 -32.24%
on 03/25/26
+6.18 (+55.38%)
since 06/05/25

Most Recent Stories

More News
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1,...

SNDX : 17.34 (-3.77%)
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered...

SNDX : 17.34 (-3.77%)
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of...

SNDX : 17.34 (-3.77%)
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host...

SNDX : 17.34 (-3.77%)
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant – – Data underscoring...

SNDX : 17.34 (-3.77%)
Syndax Announces Participation in Upcoming Investor Conferences

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger,...

SNDX : 17.34 (-3.77%)
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability...

SNDX : 17.34 (-3.77%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2026,...

SNDX : 17.34 (-3.77%)
Syndax: Q1 Earnings Snapshot

Syndax: Q1 Earnings Snapshot

SNDX : 17.34 (-3.77%)
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition...

SNDX : 17.34 (-3.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 18.96
2nd Resistance Point 18.55
1st Resistance Point 17.94
Last Price 17.34
1st Support Level 16.92
2nd Support Level 16.51
3rd Support Level 15.90

See More

52-Week High 25.59
Fibonacci 61.8% 19.09
Last Price 17.34
Fibonacci 50% 17.09
Fibonacci 38.2% 15.08
52-Week Low 8.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.